USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: DEKK-TEC, INC.
Address: 725 TOPAZ STREET
NEW ORLEANS, LA 70124-
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,108,638.00 9
SBIR Phase II $5,405,723.00 6
STTR Phase I $100,000.00 1

Award List:

PHENYLHYDRAZONES WITH ANTIESTROGEN ACTIVITIES

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $49,930.00

PHENYLHYDRAZONES WITH ANTIESTROGEN ACTIVITIES

Award Year / Program / Phase: 1991 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $440,486.00
Abstract:
Substituted benzophenone phenylhydrazones have been synthesized and have demonstrated good antiestrogen activities with low to absent intrinsic estrogenicity (in animmature rat uteri assay). 4,4(,)-dihydroxybenzophenone-2, 4-dinitrophenylhydrazone (a-007) has demonstrated a 38-percent cr with an… More

ARYL HYDRAZONES WITH ANTICANCER ACTIVITIES

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lee R Morgan
Award Amount: $49,998.00
Abstract:
Substituted benzophenone phenylhydrazones have been identified that possess antiestrogen activities with absent estrogenicity. 4, 4'-dihydroxybenzophenone-2, 4-dinitrophenylhdrazone (a-007) has demonstrated antiestrogenic activities at low concentrations and cytotoxic activities at higher… More

Pyrromethene Boron Difluorides in PDT

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lee Roy Morgan
Award Amount: $50,000.00
Abstract:
The overall objective is to develop new anticancer agents which are cytotoxic in photodynamic therapy (PDT). It has been shown by Morgan and Boyer that pyrromethene boron difluoride (P-BF2) complexes can offer this property. In Phase I, substituted (P-BF2) complexes will be prepared, characterized… More

ISOPHOSPHORAMIDE MUSTARD ANALOGS FOR CANCER THERAPY

Award Year / Program / Phase: 1998 / STTR / Phase I
Agency: HHS
Research Institution: Southern Research Institute
Principal Investigator: Morgan
Award Amount: $100,000.00
RI Contact: N/A

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lee R. Morgan
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: Lee R. Morgan
Award Amount: $126,956.00

A-007: IMMUNE MODULATION OF HPV - CERVICAL CANCER

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lee R. Morgan
Award Amount: $191,517.00
Abstract:
DESCRIPTION: (Applicant's Description) 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) has recently completed a Phase I clinical trial in advanced cancer with minimal toxicity and objective responses noted. Preliminary… More

CLINICAL DEVELOPMENT OF 4-HYDROPEROXYIFOSFAMIDE

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lee R. Morgan
Award Amount: $185,641.00
Abstract:
DESCRIPTION (provided by applicant): The objective of the proposed research is to synthesize 4-hydroperoxyifosfamide (HOO-IFOS) in sufficient quantity for evaluation in vivo against a human osteosarcoma xenograft and additional tumor xenografts of breast, lung (small cell and non-small cell) and… More

A-007: Immune Modulation of HPV - Associated Neoplasia

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: Leeroy Morgan
Award Amount: $2,300,487.00
Abstract:
DESCRIPTION (provided by applicant): 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) was originally developed as an immune modulator of immune deficiency associated cancerous growths. In a recent study, A-007 was administered as a topical gel to treat anogenital cancers associated with… More

Clinical Development of 4-Hydroperoxyifosfamide

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Lee R. Morgan
Award Amount: $539,124.00
Abstract:
DESCRIPTION (provided by applicant): 4-Hydroperoxyifosfamide (HOO-IFOS) is a stable, pre-activated form (peroxide) of 4-HO-IFOS, the initial metabolite of Ifosfamide (IFOS). Under physiological conditions HOO-IFOS under goes spontaneously ring opening and conversion to isophosphoramide mustard… More

Camptothecin Analogs for Cancer Therapy

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lee R. Morgan
Award Amount: $158,895.00
Abstract:
DESCRIPTION (provided by applicant): 7-butyl-10-aminocamptothecin (BACPT) and its water-soluble dipeptide pro-drug, are novel camptothecins that were designed to be used in the treatment of childhood neuroblastoma. These CPT analogs are lactones that have increased activity in acidic hypoxia… More

SBIR TOPIC 232 MANUFACTURE OF 4-DEMETHYL 4-CHOLESTEROLYL-PENCLOMEDINE

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Roy Lee
Award Amount: $150,000.00

4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) Phase I Clinical Tr

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lee R. Morgan
Award Amount: $272,657.00
Abstract:
DESCRIPTION (provided by applicant): The object of the proposed research is to conduct a Phase 1 clinical trial with 4-demethyl-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a carbonate derivative of 4-demethyl-penclomedine (DM-PEN) in patients with ad vanced cancer. The latter is the antitumor… More

Camptothecin Analogs for Cancer Therapy

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Lee R. Morgan
Award Amount: $837,217.00
Abstract:
DESCRIPTION (provided by applicant): 7-Butyl-10-aminocamptothecin (BACPT), as a water-soluble dipeptide pro-drug - BACPTDP, is a novel camptothecin analog that has increased activity in hypoxic/acidic tumor tissues, characteristic of fast growing cancers t hat characteristically have deficient… More

4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Lee R. Morgan – 504-583-6135
Award Amount: $1,161,453.00
Abstract:
DESCRIPTION (provided by applicant): The principal goal of this research project will be to evaluate 4-demethyl-4- cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a polychlorinated cholesterol carbonate as anticancer therapy for patients with advanced cancer in a Phase II clinical trial. During… More